Search
for

    Glossary Ixekizumab

    monoclonal antibody treating autoimmune conditions by targeting interleukin-17A

    Ixekizumab is a monoclonal antibody used to treat autoimmune conditions like psoriasis and psoriatic arthritis. It works by targeting and neutralizing interleukin-17A, a protein that plays a key role in inflammatory processes, thereby reducing symptoms and improving skin and joint health.

    Research 10 of 108

    1. Real-world single-center experience with 10 cases of generalized pustular psoriasis successfully treated with ixekizumab Journal of the American Academy of Dermatology · 2019 · 21 citations
    2. Hair whitening in a patient with psoriasis on adalimumab reversed after switching to ixekizumab JAAD case reports · 2021 · 3 citations
    3. 41824 Palmoplantar psoriasis complete clearance is achieved rapidly and sustained with ixekizumab treatment in adult and pediatric patients with moderate-to-severe plaque psoriasis Journal of the American Academy of Dermatology · 2023 · 2 citations
    4. Ixekizumab improves physical function, quality of life, and work productivity in biologic disease-modifying antirheumatic drug-naive patients with active psoriatic arthritis Journal of The American Academy of Dermatology · 2016 · 1 citations
    5. Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases Frontiers in Medicine · 2025
    6. Dissecting Cellulitis of the Scalp Successfully Treated with a Combination of Ixekizumab and Tofacitinib Journal of Inflammation Research · 2025
    7. Ixekizumab Improved Refractory Erythrodermic Psoriasis with Comorbid Diffuse Alopecia: A Case Report with 52-Week Follow-Up Clinical Cosmetic and Investigational Dermatology · 2024
    8. 42276 Long-Term Safety of Ixekizumab Treatment in Adult Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: A Post-hoc Analysis of End-Of-Study Program Data Relating to Major Adverse Cardiovascular Events Journal of the American Academy of Dermatology · 2023
    9. LB1667 Successful treatment of rare linear lichen planopilaris with ixekizumab 2023
    10. Successful treatment of rare linear lichen planopilaris with Ixekizumab Journal of dermatological treatment · 2023
    All research results →

    Learn

    — no results

    Try a deeper search in learn →

    Community

    — no results

    Try a deeper search in community →